Preoperative Omega-3 Polyunsaturated Fatty Acids in Morbidly Obese to Reduce Liver Volume and Steatosis

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

August 7, 2020

Conditions
Morbid Obesity D009765
Interventions
DRUG

Omega-3 Fatty Acid

The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.

OTHER

Placebo

The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.

Trial Locations (2)

34000

CHU de Montpellier - Chirurgie digestive, Montpellier

06200

CHU de Nice - Chirurgie Digestive- Hôpital Archet, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT03006016 - Preoperative Omega-3 Polyunsaturated Fatty Acids in Morbidly Obese to Reduce Liver Volume and Steatosis | Biotech Hunter | Biotech Hunter